Physician profile
John Michael Elchinger
NPI 1629505581
$2,330.57
in general payments reported to CMS, 2019-2025
19 companies · $459 in 2025
The $459 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $39.16 · 2021: $310 · 2022: $591 · 2023: $249 · 2024: $283 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $446.71 | 2019-2025 | Rocklatan, Tryptyr, Rhopressa |
| Abbvie INC. | $324.91 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $283.50 | 2022-2025 | Infuse, Xiidra, Miebo |
| Johnson & Johnson Vision Care, INC. | $276.03 | 2022-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $194.75 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $165.69 | 2019-2022 | |
| Horizon Therapeutics Plc | $132.71 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $103.69 | 2021 | |
| Biotissue Holdings INC. | $72.32 | 2022-2023 | |
| Thea Pharma INC. | $50.80 | 2024-2025 | Iyuzeh |
| Allergan, INC. | $48.37 | 2020-2022 | |
| Dompe US, INC. | $48.27 | 2024-2025 | Oxervate |
| Amgen INC. | $43.37 | 2024 | Tepezza |
| Aerie Pharmaceuticals, INC. | $33.42 | 2021 | |
| Coopervision INC. | $27.11 | 2021-2023 | Myday Contact Lens |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $21.77 | 2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $20.78 | 2025 | Syfovre |
| Oyster Point Pharma, INC. | $20.20 | 2022 | |
| Synergeyes, INC. | $16.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Elchinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.